Prognostic impact of cyclin D1, cyclin E and P53 on gastroenteropancreatic neuroendocrine tumours

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 1, 2013, Pages 419-422

  Liu, Shu Zheng ^a,b   Zhang, Fang ^c   Chang, Yu xi ^a   Ma, Jie ^a   Li, Xu ^a   Li, Xiao Hong ^a   Fan, Jin Hu ^d   Duan, Guang Cai ^a   Sun, Xi Bin ^b  

^a ZHENGZHOU UNIVERSITY   (China)

^b Henan Cancer Research and Control Office   (China)

^c HENAN UNIVERSITY OF CHINESE MEDICINE   (China)

^d PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Cyclin D1; Cyclin E; Gastroenteropancreatic neuroendocrine tumor; Immunohistochemistry; P53

Indexed keywords

EID: 84877128637     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.1.419     Document Type: Article

References (20)

1. Ahn MJ, Kim BH, Sohn JH, et al (1998). Expression of Cyclin D1 and Cyclin E in human gastric carcinoma and its clinicopathologic significance. J Korean Med Sci, 13, 513-18.
2. Bosman F, Carneiro F (2010). WHO classifification of tumours, pathology and genetics otumours of the digestive system. Lyon, IARC Press.
3. Cho MY, Kim JM, Sohn JH, et al (2012). Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study. Cancer Res Treat, 44, 157-65.
4. Corin I, Larsson L, Bergstrom J, et al (2010). A study of the expression of Cyclin E and its isoforms in tumor and adjacent mucosa, correlated to patient outcome in early colon cancer. Acta Oncol, 49, 63-9.
5. Florenes VA, Faye RS, Maelandsmo GM, et al (2000). Levels of Cyclin D1 and D3 in malignant melanoma: deregulated Cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res, 6, 3614-20.
6. Grabowski P, Schrader J, Wagner J, et al (2008). Loss of nuclear p27 expression and its prognostic role in relation to Cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res, 14, 7378-84.
7. Heah KG, Hassan MI, Huat SC (2011). p53 Expression as a marker of microinvasion in oral squamous cell carcinoma. Asian Pac J Cancer Prev, 12, 1017-22.
8. Hemminki K, Li X (2001). Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer, 92, 2204-10.
9. Ioachim E. (2008). Expression patterns of Cyclins D1, E and Cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features. Int J Clin Pract, 62, 1736-43.
10. Kamai T, Takagi K, Asami H, et al (2001). Decreasing of p27(Kip1)and Cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer, 84, 1242-51.
11. Kawahara M, Kammori M, Kanauchi H, et al (2002). Immunohistochemical prognostic indicators of gastrointestinal carcinoid tumours. Eur J Surg Oncol, 28, 140-46.
12. Kishimoto I, Mitomi H, Ohkura Y, et al (2008). Abnormal expression of p16(INK4a), Cyclin D1, Cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas. J Surg Oncol, 98, 60-6.
13. Lepage C, Bouvier AM, Phelip JM, et al (2004). Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut, 53, 549-53.
14. Modlin IM, Lye KD, Kidd M (2003). A 5-decade analysis of 13,715 carcinoid tumors. Cancer, 97, 934-59.
15. Quaedvlieg PF, Visser O, Lamers CB, et al (2001). Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol, 12, 1295-300.
16. Richter J, Wagner U, Kononen J, et al (2000). High-throughput tissue microarray analysis of Cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol, 157, 787-94.
17. Rorstad O (2005). Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol, 89, 151-60.
18. Sakaguchi T, Watanabe A, Sawada H, et al (1998). Prognostic value of Cyclin E and p53 expression in gastric carcinoma. Cancer, 82, 1238-43.
19. Sumiyoshi Y, Kakeji Y, Egashira A, et al (2006). Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res, 12, 5112-17.
20. Williams ED, Sandler M (1963). The classification of carcinoid tum ours. Lancet, 1, 238-39.